Pumitamig + Folfox + Capox + Nivolumab

Phase 2/3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Conditions

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Trial Timeline

Mar 31, 2026 → Sep 11, 2032

NCT ID

NCT07221149

About Pumitamig + Folfox + Capox + Nivolumab

Pumitamig + Folfox + Capox + Nivolumab is a phase 2/3 stage product being developed by Bristol Myers Squibb for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07221149. Target conditions include Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07221149	Phase 2/3	Recruiting	Mar 31, 2026	Sep 11, 2032	Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Competing Products

15 competing products in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion	AbbVie	Phase 2	52
Onureg + Venetoclax	AbbVie	Phase 1/2	41
Acalabrutinib + Rituximab + Chlorambucil	AstraZeneca	Phase 3	77
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel	Merck	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine	Roche	Phase 2	52
Rituximab + ACVBP regimen plus Pegfilgrastim	Amgen	Phase 2	51
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
PF-08634404 + Chemotherapy + Nivolumab	Pfizer	Phase 2/3	64
Nivolumab + Relatlimab	Bristol Myers Squibb	Approved	84
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine	Bristol Myers Squibb	Phase 2	51
Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX	Bristol Myers Squibb	Phase 2/3	64

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved